United States · FDA National Drug Code directory

Ondansetron

A source-listed medicine record.

Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.

Medicine identity

Source reference
71335-0650_e5cd8042-5934-4ebf-98f2-90e3d5b48beb
Product NDC
71335-0650
Form
TABLET, ORALLY DISINTEGRATING
Composition / generic term
Ondansetron
Labeler
Bryant Ranch Prepack
Marketing category
ANDA
Marketing start / end (source format)
20100412
Source listing expiry
20261231

Source-listed ingredients

  • ONDANSETRON — 4 mg/1

These values do not establish equivalence or a dose recommendation.

Packages

  • 90 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-0650-0) · 71335-0650-0
  • 30 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-0650-1) · 71335-0650-1
  • 20 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-0650-2) · 71335-0650-2
  • 10 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-0650-3) · 71335-0650-3
  • 6 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-0650-4) · 71335-0650-4
  • 60 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-0650-5) · 71335-0650-5
  • 9 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-0650-6) · 71335-0650-6
  • 5 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-0650-7) · 71335-0650-7
  • 15 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-0650-8) · 71335-0650-8
  • 3 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-0650-9) · 71335-0650-9

Source and coverage

Open FDA National Drug Code directory

Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.

Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.

Browse United States records →